Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CB | P42338 | 19/20 | 0.58 |
| ▸ | PIK3CD | O00329 | 9/20 | 0.58 |
| ▸ | PIK3CA | P42336 | 9/20 | 0.58 |
| ▸ | PIK3CG | P48736 | 9/20 | 0.58 |
| ▸ | MTOR | P42345 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1638958 | 0.88 | PIK3CA (0.53) | PIK3CBPIK3CDPIK3CAPIK3CGMTOR | |
| SCHEMBL13449184 | 0.87 | PRKDC (0.58) | PIK3CBPIK3CDPIK3CAPIK3CGMTOR | |
| SCHEMBL1637213 | 0.84 | PIK3CB (0.63) | PIK3CBPIK3CDPIK3CAPIK3CGKCNH2 | |
| SCHEMBL1638322 | 0.84 | PRKDC (0.55) | PIK3CBPIK3CDPIK3CAPIK3CG | |
| SCHEMBL1639150 | 0.80 | PIK3CB (0.69) | PIK3CBPIK3CDPIK3CAPIK3CG | |
| Bromide SCHEMBL1639537 | 0.79 | PIK3CB (0.68) | PIK3CBPIK3CDPIK3CAPIK3CG | |
| SCHEMBL1863568 | 0.79 | PIK3CB (0.56) | PIK3CBPIK3CDPIK3CAPIK3CGMTOR | |
| SCHEMBL1639036 | 0.79 | PIK3CB (0.70) | PIK3CBPIK3CDPIK3CAPIK3CG | |
| SCHEMBL24714393 | 0.79 | PRKDC (0.59) | PIK3CBPIK3CDPIK3CAPIK3CGMTOR | |
| Bromide SCHEMBL1868689 | 0.79 | PIK3CB (0.55) | PIK3CBPIK3CDPIK3CAPIK3CGMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2697220-B1 | CHROMENONE COMPOUNDS AS PI 3-KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2016-01-13 | — | — | EP | disclosed |
| EP-2697220-B1 | CHROMENONE COMPOUNDS AS PI 3-KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2016-01-13 | — | — | EP | disclosed |
| EP-2697220-A1 | CHROMENONE COMPOUNDS AS PI 3 -KINASE INHIBITORS FOR THE TREATMENT OF CANCER | AstraZeneca AB (SE) | 2014-02-19 | — | — | EP | disclosed |
| US-20140038937-A1 | Chromenone Derivatives | ASTRAZENECA AB (SE) | 2014-02-06 | — | — | US | disclosed |
| US-20140038937-A1 | Chromenone Derivatives | ASTRAZENECA AB (SE) | 2014-02-06 | — | — | US | disclosed |
| US-20140038937-A1 | Chromenone Derivatives | ASTRAZENECA AB (SE) | 2014-02-06 | — | — | US | disclosed |
| US-8530470-B2 | Chromenone derivatives | ASTRAZENECA AB (SE) | 2013-09-10 | — | — | US | disclosed |
| US-8530470-B2 | Chromenone derivatives | ASTRAZENECA AB (SE) | 2013-09-10 | — | — | US | disclosed |
| US-8530470-B2 | Chromenone derivatives | ASTRAZENECA AB (SE) | 2013-09-10 | — | — | US | disclosed |
| US-20120264731-A1 | CHROMENONE DERIVATIVES | ASTRAZENECA AB (SE) | 2012-10-18 | — | — | US | disclosed |
| US-20120264731-A1 | CHROMENONE DERIVATIVES | ASTRAZENECA AB (SE) | 2012-10-18 | — | — | US | disclosed |
| US-20120264731-A1 | CHROMENONE DERIVATIVES | ASTRAZENECA AB (SE) | 2012-10-18 | — | — | US | disclosed |
| WO-2012140419-A1 | CHROMENONE COMPOUNDS AS PI 3 -KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2012-10-18 | — | — | WO | disclosed |
| WO-2012140419-A1 | CHROMENONE COMPOUNDS AS PI 3 -KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2012-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140038937-A1 | Chromenone Derivatives | RB1, CYP11B1, CCND1 | PIK3CB 3286/4885PIK3CD 2843/4885PIK3CA 1609/4885 |
| US-20120264731-A1 | CHROMENONE DERIVATIVES | RB1, CYP11B1, CCND1 | PIK3CB 3286/4885PIK3CD 2843/4885PIK3CA 1609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.